Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-06-04 pm EDT 		5-day change 1st Jan Change
13.95 USD +0.29% Intraday chart for Alvotech -0.07% +21.52%
11:44am Alvotech Signs Biosimilar Marketing Deal With Stada MT
11:27am Alvotech Expands Alliance with STADA to Include Denosumab Biosimilar MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Alvotech and STADA add to Strategic Alliance through Denosumab Partnership
GL
Teva And Alvotech Announce Launch Of SIMLANDI (Adalimumab-ryvk) Injection In The U.S.
AQ
Alvotech : Main Results of Annual and Extraordinary General Meeting
PU
Alvotech : Granting of Stock Options and Restricted Share Units
PU
Alvotech : Managers' transactions Alvotech Managers' Transaction Notification Linda McGoldrick
PU
Alvotech : Managers' transactions Alvotech Managers' Transaction Notification Richard Davies
PU
Alvotech : Managers' transactions Alvotech Managers' Transaction Notification Lisa Graver
PU
Alvotech : Managers' transactions Alvotech Managers' Transaction Notification Ann Merchant
PU
Alvotech Announces Strategic Refinancing Agreement
GL
Alvotech : Corporate Overview June 2024
PU
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
GL
Alvotech : Transactions of Managers and Closely Associated Persons
PU
Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.
AQ
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GL
Alvotech : and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
PU
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
GL
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
AQ
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
GL
Alvotech S.A. Annual General Meeting to be held June 7, 2024
GL
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. News Alvotech
  5. Press Releases